Call for Papers: International Conference on Nanotechnologies and Biomedical Engineering (ICNBME)

7 - 8 July 2011, Chisinau, Republic of Moldova.
ICNBME-2011 continues the series of International Conferences in the field of nanotechnologies and biomedical engineering. The conference aims at bringing together scientists and engineers dealing with fundamental and applied research for reporting on the latest theoretical developments and applications in the fields involved.

Contributing papers are called in the following areas:

  • Nanotechnologies and Nanomaterials;
  • Micro- and Nano-objects, Nanostructured and highly integrated systems, Biophysics;
  • Plasmonics and Metamaterials;
  • Biomedical Optics and Lasers;
  • Sensors and Transducers;
  • Terahertz spectroscopy;
  • Biomedical Instrumentation and Devices;
  • Health Care Management;
  • Medical Imaging, Image and Signal Processing;
  • Radiation Protection and Dosymetry, Biological Effect of Radiation;
  • Biomedical Engineering Education;
  • Information Technologies for Health Care, Telemedicine and E-Health;
  • Other topics in biomedical engineering.

Submission of Papers
Contributed papers should be subscribed on four-six pages and submitted by e-mail in Microsoft Word format to This email address is being protected from spambots. You need JavaScript enabled to view it.

Accepted papers will be included in the Conference Proceedings, distributed to the participants at the beginning of the conference.

Deadlines:

  • May 1 st, 2011 - Submission of extended abstracts
  • May 15th, 2011 - Notification of acceptance
  • June 15th, 2011 - Advanced Conference Registration
  • June 20th, 2011 - Hotel/trip reservation
  • July 1th, 2011 --Deadline for Registration Fee refunding
  • July 5-6th, 2011 - Arrival and Registration of Participants
  • July 7th, 2011 - Opening of the Conference
  • July 9 th, 2011 - Social Program
  • July 9-10th, 2011 - Departure of Participants

For further information and registration, please visit:
http://www.icnbme.sibm.md

Most Popular Now

Study finds lack of racial diversity in cancer dru…

New research published in JAMA Oncology has found a lack of racial and ethnic diversity in clinical trials for cancer drugs. The study - conducted by researchers from UBC...

Preventing tumor metastasis

Researchers at the Paul Scherrer Institute, together with colleagues from the pharmaceutical company F. Hoffmann-La Roche AG, have taken an important step towards the dev...

A new drug could revolutionize the treatment of ne…

The international team of scientists from Gero Discovery LLC, the Institute of Biomedical Research of Salamanca, and Nanosyn, Inc. has found a potential drug that may pre...

Interactions discovered in cells insulating nerve …

Schwann cells form a protective sheath around nerve fibres and ensure that nerve impulses are transmitted rapidly. If these cells are missing or damaged, severe neurologi...

Roche's first FDA-approved tumour-agnostic medicin…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has approved Rozlytrek™ (entrectinib) for the treatment of adults with R...

Anniversary of the pivotal RE-LY® trial marks a de…

Boehringer Ingelheim today announces the ten-year anniversary of the RE-LY® trial publication(1-3) recognising the contribution made in the decade since by patients, heal...

AstraZeneca agrees to buy US FDA Priority Review V…

AstraZeneca announced that it has agreed to buy a US Food and Drug Administration (FDA) Priority Review Voucher (PRV) for a total cash consideration of $95m from a subsid...

The Pfizer Foundation invests in 20 organizations …

The Pfizer Foundation announced 20 grants* to help non-governmental organizations (NGOs), non-profits and social enterprises address critical health challenges related to...

FDA grants Fast Track designation for Farxiga in c…

AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of Farxiga (dapagliflozin) to delay the ...

Pfizer invests half billion dollars to advance sta…

Pfizer announced an additional half billion dollar investment for the construction of its state-of-the-art gene therapy manufacturing facility in Sanford, North Carolina...

Amgen and Allergan announce positive top-line resu…

Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced positive top-line results from a comparative clinical study evaluating the efficacy and safety of ABP 798...

Breast cancer can form 'sleeper cells' after drug …

Breast cancer medicines may force some cancer cells into 'sleeper mode', allowing them to potentially come back to life years after initial treatment. These are the early...